BioCryst Pharmaceuticals Inc. sold its European ORLADEYO business to Neopharmed Gentili for $250 million upfront. The deal includes potential future milestones worth up to $14 million based on sales in Central and Eastern Europe. This divestiture allows BioCryst to focus on driving ORLADEYO sales in the US and improve its operating margin.

Despite losing European revenue, BioCryst is still on track to meet the upper half of its 2025 revenue guidance range of $580 million to $600 million. The company specializes in developing oral small-molecule and injectable protein therapeutics to treat rare diseases. Investors may find potential in BCRX, but other AI stocks offer greater upside potential with less downside risk.

Read more at Yahoo Finance: BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market